Juno Therapeutics Inc (NASDAQ:JUNO) shares were up 3.6% during trading on Wednesday . The stock traded as high as $28.52 and last traded at $28.45, with a volume of 1,019,223 shares traded. The stock had previously closed at $27.47.

Several research analysts have commented on JUNO shares. Morgan Stanley lifted their price objective on shares of Juno Therapeutics from $48.00 to $50.00 in a research note on Friday, April 8th. FBR & Co reaffirmed a “buy” rating on shares of Juno Therapeutics in a research note on Monday, June 6th. Vetr lowered shares of Juno Therapeutics from a “strong-buy” rating to a “buy” rating and set a $53.00 target price for the company. in a research note on Monday, June 6th. Maxim Group reissued a “buy” rating and set a $80.00 target price (up from $78.00) on shares of Juno Therapeutics in a research note on Monday, April 11th. Finally, SunTrust Banks Inc. reissued a “buy” rating and set a $50.00 target price on shares of Juno Therapeutics in a research note on Wednesday, April 20th. One analyst has rated the stock with a sell rating, three have given a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company. The company has a consensus rating of “Buy” and an average target price of $54.84.

The firm’s market capitalization is $2.90 billion. The firm has a 50 day moving average price of $39.26 and a 200-day moving average price of $37.74.

Juno Therapeutics (NASDAQ:JUNO) last posted its earnings results on Monday, May 9th. The biopharmaceutical company reported ($0.78) earnings per share for the quarter, missing the consensus estimate of ($0.52) by $0.26. The company earned $9.80 million during the quarter, compared to analysts’ expectations of $4.83 million. During the same period last year, the firm posted ($0.30) EPS. On average, equities research analysts anticipate that Juno Therapeutics Inc will post ($2.28) EPS for the current year.

In other Juno Therapeutics news, General Counsel Bernard J. Cassidy sold 3,116 shares of Juno Therapeutics stock in a transaction that occurred on Thursday, May 19th. The stock was sold at an average price of $39.03, for a total transaction of $121,617.48. Following the transaction, the general counsel now owns 55,511 shares of the company’s stock, valued at $2,166,594.33. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, Director Richard Klausner sold 12,000 shares of Juno Therapeutics stock in a transaction that occurred on Friday, June 24th. The stock was sold at an average price of $40.71, for a total value of $488,520.00. Following the transaction, the director now directly owns 846,799 shares in the company, valued at approximately $34,473,187.29. The disclosure for this sale can be found here.

Other hedge funds and institutional investors have recently added to or reduced their stakes in the company. BNP Paribas Arbitrage SA raised its position in Juno Therapeutics by 27.0% in the fourth quarter. BNP Paribas Arbitrage SA now owns 51,206 shares of the biopharmaceutical company’s stock valued at $2,252,000 after buying an additional 10,884 shares during the period. US Bancorp DE raised its position in Juno Therapeutics by 1.8% in the fourth quarter. US Bancorp DE now owns 88,700 shares of the biopharmaceutical company’s stock valued at $3,900,000 after buying an additional 1,600 shares during the period. BBR Partners LLC purchased a new position in Juno Therapeutics during the fourth quarter valued at approximately $1,539,000. Baillie Gifford & Co. purchased a new position in Juno Therapeutics during the fourth quarter valued at approximately $12,312,000. Finally, ProShare Advisors LLC purchased a new position in Juno Therapeutics during the fourth quarter valued at approximately $3,674,000.

Juno Therapeutics, Inc (Juno) is a biopharmaceutical company. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells. Juno’s product candidates, JCAR015, JCAR017 and JCAR014, utilize CAR technology to target CD19, a protein expressed on the surface of various B cell leukemias and lymphomas.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.